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Abstract: 
3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one 
(mexedrone) appeared in 2015 and was advertised by UK Internet retailers 
as a non-controlled mephedrone derivative (2-(methylamino)-1-(4-
methylphenyl)propan-1-one), which was of particular interest to countries 
who operate generic drugs legislation. This study describes the synthesis 
and analytical characterization of mexedrone and differentiation from its 
isomer, N-methoxymephedrone, which was predicted to be a suitable 
candidate before the identity of mexedrone was revealed. A full analytical 
characterization is described for the first time using various 
chromatographic, spectroscopic and mass spectrometric platforms and X-
ray crystal structure analysis. The analytical data obtained for a vendor 
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sample were consistent with the synthesized mexedrone reference 
standard and analytical differentiation between the mexedrone and N-
methoxymephedrone positional isomers was achieved. Furthermore, α-
chloromethylmephedrone was identified as a by-product during mexedrone 
synthesis. All three substances were also studied for their uptake and 
releasing properties at dopamine transporters (DAT), norepinephrine 
transporters (NET) and serotonin transporters (SERT) using in vitro 
monoamine transporter assays in rat brain synaptosomes and compared to 
mephedrone. Mexedrone was a weak non-selective uptake blocker with 
IC50 values in the low µM range. It was also devoid of releasing activity at 
DAT and NET, but displayed weak releasing activity at SERT (EC50 = 2.5 
µM). The isomer N-methoxymephedrone was found to be a weak uptake 
blocker at DAT, NET and SERT and a fully efficacious substrate-type 
releasing agent across all three transporters with EC50 values in the low 
micromolar range. The synthesis by-product α-chloromethylmephedrone 
was inactive in all assays. 
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Abstract 
 
3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one (mexedrone) 
appeared in 2015 and was advertised by UK Internet retailers as a non-
controlled mephedrone derivative (2-(methylamino)-1-(4-
methylphenyl)propan-1-one), which was of particular interest to countries who 
operate generic drugs legislation. This study describes the synthesis and 
analytical characterization of mexedrone and differentiation from its isomer, N-
methoxymephedrone, which was predicted to be a suitable candidate before 
the identity of mexedrone was revealed. A full analytical characterization is 
described using various chromatographic, spectroscopic and mass 
spectrometric platforms and X-ray crystal structure analysis. The analytical 
data obtained for a vendor sample were consistent with the synthesized 
mexedrone reference standard and analytical differentiation between the 
mexedrone and N-methoxymephedrone positional isomers was achieved. 
Furthermore, α-chlo omethylmephedrone was identified as a by-product 
during mexedrone synthesis. All three substances were also studied for their 
uptake and releasing properties at dopamine transporters (DAT), 
norepinephrine transporters (NET) and serotonin transporters (SERT) using in 
vitro monoamine transporter assays in rat brain synaptosomes and compared 
to mephedrone. Mexedrone was a weak non-selective uptake blocker with 
IC50 values in the low µM range. It was also devoid of releasing activity at 
DAT and NET, but displayed weak releasing activity at SERT (EC50 = 2.5 µM). 
The isomer N-methoxymephedrone was found to be a weak uptake blocker at 
DAT, NET and SERT and a fully efficacious substrate-type releasing agent 
across all three transporters with EC50 values in the low micromolar range. 
The synthesis by-product α-chloromethylmephedrone was inactive in all 
assays. 
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Introduction 
 
Mephedrone (4-methylmethcathinone) (Figure 1A) is a synthetic ring-
substituted cathinone derivative, which was introduced onto the new 
psychoactive substances (NPS) drug market nearly a decade ago. It became 
a popular stimulant and was placed under legislative control measures across 
Europe in December 2010 and subsequently towards the end of 2015 it was 
subjected to international control measures by its addition to Schedule 2 of 
the Convention on Psychotropic Substances of 1971.[1-2] Although 
mephedrone was introduced onto the NPS drug market as a new 
psychostimulant, the history of mephedrone goes back to 1929 when the 
synthesis was first described by Saem de Burnaga Sanchez.[3] This route 
involved the bromination of 4-methylpropiophenone, which yielded 4-methyl-
2-bromopropiophenone that was then reacted with methylamine hydrochloride 
and triethylamine to give 4-methylmethcathinone as a racemic mixture.[3] 
 
Mephedrone has been encountered as a “legal high” and on the illicit drug 
market masquerading as cocaine (in powder form), MDMA (in tablet form) and 
as an adulterant.[4-7] According to the 2016 European Drugs Market Report 
produced by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), mephedrone has created a specific demand and carved its own 
distinct market share.[8] The drug remains a popular stimulant on the illicit 
drug market and is specifically sought out by some users, including chronic 
and marginalised drug users, possibly due to some pharmacological 
similarities with 3,4-methylenedioxymethamphetamine (MDMA).[8,9] 
Mephedrone is regarded as one of the new substances to be causing a wide 
range of serious harms throughout Europe, including acute poisonings and 
harms resulting from changes in the pattern of drug injection.[8,10] In Ireland, it 
has been observed that heroin users are now injecting mephedrone (and α-
PVP) when heroin is in short supply. Furthermore, analysis of materials (e.g. 
precursors) seized at clandestine laboratories within Europe suggest that a 
range of substances, including mephedrone, are being synthesized in 
Europe.[8] Not surprisingly, 2014 seizure data compiled by the EMCDDA 
reported 1645 mephedrone seizures by 10 Europeans countries amounting to 
203 kilograms, the majority seized by the United Kingdom (UK) and 
Cyprus.[11] 
 
The pharmacological profile of mephedrone at monoamine receptors and 
transporters suggests that it has a high abuse liability. Several animal studies 
have demonstrated that mephedrone possesses psychostimulant activity and 
that it mimics other amphetamine-type stimulants in its ability to function as a 
efficacious substrate-type releaser at monoamine transporters.[12-16] Data from 
human-based studies have also suggested that mephedrone impairs working 
memory acutely, induces stimulant-like effects in users comparable to 
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MDMA[17,18] and disrupts cognitive function and verbal fluency.[19] It has been 
reported that mephedrone can be administered in a number of ways including 
orally, nasal insufflation, intramuscular injection, intravenous injection, rectal 
insertion and inhalation or vaporization.[20,21] Fatalities associated with its use 
have been reported throughout the literature.[22-27]  
 
It is well established at this stage that once a compound is placed under 
legislative control measures that there is a desire by NPS manufacturers to 
design and launch novel compounds that circumvent existing drugs legislation 
in order to fill the gap created in the market. Almost five years after its control, 
for example in the UK and Ireland, a replacement for mephedrone was 
eventually launched on the NPS market in August 2015. The replacement 
was reportedly almost two years in development and was specifically 
designed for markets in countries where generic cathinone bans have been 
enforced.[28] However, the months leading up to its release were intensified by 
a marketing campaign by online vendors, who only provided the website 
users with limited details such as the name of the new mephedrone analog, 
which was to be called ‘mexedrone’. During this time before its release, the 
authors attempted to predict the chemical structure of mexedrone. It was 
rationalized that the incorporation of a methoxy moiety to the terminal amine 
of the existing mephedrone molecular scaffold would be a suitable candidate 
for the NPS market, resulting in the formation of N-methoxymephedrone, 2-
(methoxy(methyl)amino)-1-(4-methylphenyl)propan-1-one. This prediction 
agreed with a chemical structure of mexedrone that was later posted on a 
Polish vendor website.[29] After its launch onto the market, however, the 
identity of mexedrone was revealed to be 3-methoxy-2-(methylamino)-1-(4-
methylphenyl)propan-1-one. The prediction suggesting the addition of a 
methoxy moiety was correct although it was not incorporated into the amine 
as inferred, but rather it was attached to position 3 in the propan-1-one 
sequence. Currently, there are limited chemical and pharmacological data 
available on mexedrone. One study identified mexedrone among samples 
seized by police officials in China.[30] Its use as a research chemical has been 
discussed on different online forums and users have compared it to 
mephedrone, describing it as a much weaker stimulant.[31-33] 
 
This study describes the synthesis and analytical characterization of 
mexedrone and differentiation from its N-methoxy positional isomer, named 
N-methoxymephedrone (Figure 1A). This study was triggered by the hype 
surrounding the novel mephedrone analog and the purchase of a sample 
advertised as mexedrone from an internet vendor based in the UK. Various 
chromatographic, spectroscopic and mass spectrometric platforms were 
employed followed by structural investigations using X-ray crystal structure 
analysis. In order to assess whether mexedrone and N-methoxymephedrone 
displayed mephedrone-like effects in vitro, their uptake and releasing 
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properties were studied at dopamine transporters (DAT), norepinephrine 
transporters (NET) and serotonin transporters (SERT) using in vitro 
monoamine transporter assays in rat brain synaptosomes. 
 
 
Experimental 
 
Reagents and standards 
 
All reagents and dry solvents used in the syntheses were obtained from 
Sigma Aldrich Ltd (Arklow, Co. Wicklow, Ireland). LC-MS grade solvents were 
obtained from Fisher Scientific (Dublin, Ireland). A vendor sample of 
mexedrone was obtained from an online vendor based in the UK.  
 
Syntheses 
 
2-(Methoxy(methyl)amino)-1-(4-methylphenyl)propan-1-one (N-
methoxymephedrone) 
 
A mixture of alpha-bromo-4-methylpropiophenone (a) (227 mg, 1 mmol), N,O-
dimethylhydroxylamine hydrochloride (116 mg, 1.2 mmol) and N,N-
diisopropylethylamine (516 mg, 4 mmol) was heated at 125-130 oC for 1.5 h 
(2 reactions; each in a Supelco micro reaction vessel, 2 mL) and then allowed 
to cool to room temperature. The mixture was partitioned between aqueous 
hydrochloric acid (2 M) and diethyl ether. The aqueous layer was further 
washed with diethyl ether and then made basic with aqueous sodium 
hydroxide (10 M). This was extracted with dichloromethane, the organic 
extract was dried (anhydrous magnesium sulfate) and the volatiles were 
removed under vacuum to afford a yellow oil (b) (133 mg, 0.6 mmol, 63%). 
Formation of the hydrochloride salt using a solution (2 M) of hydrogen chloride 
in diethyl ether, followed by trituration with tert.-butyl methyl ether, afforded a 
colorless solid (60 mg, 0.25 mmol, 25%): Melting point: 80-82 oC; 1H NMR (d6 
DMSO) δ 7.94 (d; J = 8.3 Hz; 2H; Ar-H), 7.33 (d; J = 8.3 Hz; 2H; Ar-H), 4.45 
(q; J = 6.8 Hz; 1H; C(O)CHN), 3.26 (s; 3H; OCH3), 2.61 (s; 3H, NCH3) , 2.38 
(s; 3H; Ar-CH3) and 1.20 (d; J = 6.8 Hz; 3H; CHCH3) ppm; δ 13C NMR (d6 
DMSO) 198.46 (CO), 143.96 (Ar-C), 133.75 (Ar-C), 129.55 (Ar-CH), 129.30 
(Ar-CH), 66.88 (CH), 59.56 (OCH3), 41.29 (NCH3), 21.63 (Ar-CH3) and 12.63 
(broad, CHCH3) ppm. ESI HRMS observed m/z 208.13297 (theory [M + H]+: 
C12H18NO2+, m/z 208.13321, ∆ = -1.15 ppm).  
 
3-Methoxy-1-(4-methylphenyl)propan-1-one 
 
A mixture of 3-chloro-1-(4-methylphenyl)propan-1-one (c) (1.00 g, 5.47 
mmol), sodium iodide (1.00 g, 6.67mmol) and sodium methoxide (1.00 g, 
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18.52 mmol) in methanol (20 mL) was stirred overnight at room temperature. 
The mixture was then partitioned between dichloromethane and water. The 
organic layer was collected, dried (anhydrous magnesium sulfate) and the 
volatiles were removed to afford colorless crystals  (d) (900 mg, 5 mmol, 
92%). Melting point: 32-34 oC; 1H NMR (d6 DMSO) δ 7.92–7.84 (m; 2H; Ar-H); 
7.33–7.26 (m; 2H; Ar-H); 3.84 (t; J = 6.5 Hz; 2H, CH2O); 3.40 (s; 3H; CH3); 
3.24 (t; J = 6.5 Hz; 2H; COCH2) and 2.43 (s; 3H; CH3) ppm.13C NMR (d6 
DMSO) δ 197.95 (CO); 143.96 (Ar-C); 134.54 (Ar-C); 129.27 (Ar-CH); 128.25 
(Ar-CH); 68.00 (CH2OCH3); 58.92 (CH3); 38.57 (COCH2) and 21.63 (Ar-CH3) 
ppm. ESI HRMS observed m/z 179.10699 (theory [M + H]+: C11H15O2+, m/z 
179.10666, ∆ = 1.88 ppm).  
 
3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one (mexedrone) 
 
A solution of bromine (674 mg, 218 µL, 4.2 mmol) in dichloromethane (7.5 
mL) was added to a solution of 3-methoxy-1-(4-methylphenyl)propan-1-one 
(750 mg, 4.2 mmol) in dichloromethane (15 mL). The mixture was stirred for 
30 min at room temperature. Drying (anhydrous magnesium sulfate) and 
removal of the volatiles afforded a light brown oil (e). This was dissolved in 
acetonitrile (7.5 mL) and methanolic methylamine (1.5 mL, 8 M) was added. 
The mixture was stirred at room temperature for 4 h and the volatiles were 
then removed under vacuum. The residue was partitioned between 
dichloromethane and water. The organic layer was collected, dried 
(anhydrous magnesium sulfate) and the volatiles were removed to afford a 
brown oil (f). Formation of the hydrochloride salt using a solution (2 M) of 
hydrogen chloride in diethyl ether, followed by washing with acetone, afforded 
a colorless solid (426 mg, 1.75 mmol). This was recrystallized from ethanol to 
afford colorless crystals (181 mg, 0.74 mmol, 17%): Melting point: 190-192 
oC; 1H NMR (d6 DMSO) δ 9.65 (s; 1H; NH), 9.21(s; 1H; NH); 7.95 (d; J = 8.4 
Hz; 2H; Ar-H), 7.43 (d; J = 8.0 Hz; 2H; Ar-H), 5.38 (m; 1H; C(O)CHN), 4.00 
(dd; J = 3.2 Hz; 1H; 1H from CH2OCH3), 3.82 (dd; J = 11.3, 3.2 Hz; 1H; 1H 
from CH2OCH3); 3.18 (s; 3H; OCH3), 2.60 (s; 3H; NHCH3) and 2.43 (s; 3H; Ar-
CH3) ppm.13C NMR (d6 DMSO) δ 193.39 (CO), 145.82 (Ar-C), 131.31 (Ar-C), 
130.13 (Ar-CH), 129.26 (Ar-CH), 69.57 (CH2), 63.39 (CH), 59.17 (OCH3), 
31.94 (NCH3) and 21.45 (Ar-CH3) ppm. ESI HRMS observed m/z 208.13374 
(theory [M + H]+: C12H18NO2+, 208.13321, ∆ = 2.58 ppm). 
 
3-Chloro-2-(methylamino)-1-(4-methylphenyl)propan-1-one (α-
chloromethylmephedrone) 
 
A solution of bromine (674 mg, 218 µL, 4.2 mmol) in dichloromethane (7.5 
mL) was added to a solution of 3-methoxy-1-(4-methylphenyl)propan-1-one 
(g) (767 mg, 4.2 mmol) in dichloromethane (15 mL). The mixture was stirred 
for 30 min at room temperature. Drying (anhydrous magnesium sulfate) and 
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removal of the volatiles afforded a light brown oil (h). This was dissolved in 
acetonitrile (7.5 mL) and methanolic methylamine (1.5 mL, 8 M) was added. 
The mixture was stirred at room temperature for 4 h and the volatiles were 
then removed under vacuum. The residue was partitioned between 
dichloromethane and water. The organic layer was collected, dried 
(anhydrous magnesium sulfate) and the volatiles were removed to afford a 
brown oil (i). Formation of the hydrochloride salt using a solution (2 M) of 
hydrogen chloride in diethyl ether, followed by washing with acetone, afforded 
a light beige powder (218 mg) which was recrystallized from ethanol to afford 
colorless hydrochloride salt crystals (84 mg, 0.34 mmol, 8%). Melting point: 
166-168 oC; 1H NMR (d6 DMSO) δ 9.51 (s; 1H; NH), 9.35 (s; 1H; NH), 7.79 (d; 
J = 8.0 Hz; 2H; Ar-CH), 7.44 (d; J = 8.0 Hz; 2H; Ar-CH), 6.09 (dd; J = 8.5, 4.5 
Hz; 1H, CH), 3.70–3.45 (m; 2H; CH2), 2.67 (dist. t; J = 5.0 Hz; 3H; NCH3), and 
2.43 (s; 3H; Ar-CH3) ppm. 13C NMR (d6 DMSO) δ 190.83 (CO), 145.33 (Ar-C), 
130.62 (Ar-C), 129.64 (Ar-C), 129.24 (Ar-C), 51.75 (CH), 49.49 (CH2), 33.05 
(CH3), and 21.32 (CH3) ppm. ESI HRMS observed m/z 212.08357 (theory [M 
+ H]+: C11H15ONCl+, 212.08367, ∆ = - 0.45247 ppm) 
 
 
Instrumentation 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Samples were prepared to give a 1 mg/mL solution in methanol and analyzed 
on an Agilent 6890N GC coupled to 5975 Mass Selective Detector (Agilent, 
Little Island, Cork, Ireland). A HP-ULTRA 1 column (12 m × 0.2 mm × 0.33 
µm) was used with helium carrier gas at a constant flow of 1 mL/min and a 
split ratio of 50:1. The injector was set at 250 °C and the transfer line at 280 
°C. The initial oven temperature was 60 °C, held for 2 min then ramped at 25 
°C/min to 295 °C with a hold time of 3 min. The mass spectra were collected 
after a 1.5 min solvent delay time. The ionization energy was set at 70 eV and 
the mass range was m/z 40-450. The total run time was 14.40 min. 
 
Liquid chromatography-mass spectrometry (LC-MS) 
 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped 
with a G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A 
column oven (COLCOM) (Agilent, Little Island, Cork). Separation was 
obtained on an Allure PFP Propyl column (5 µm, 50 x 2.1 mm) Restek 
(Bellefonte, PA, USA). Mobile phase A consisted of 0.1% formic acid in water, 
whereas, mobile phase B consisted of 0.1% formic acid in acetonitrile. The 
Agilent LC-MSD settings were as follows: positive electrospray mode, 
capillary voltage 3500 V, drying gas (N2) 12 L/min at 350 oC, nebulizer gas 
(N2) pressure 50 psi, scan mode m/z 70-500, fragmentor voltage 50 and 110 
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V. Samples for LC-MS analysis were dissolved in acetonitrile/water (1:1, 
containing 0.1% formic acid) at a concentration of 10 µg/mL. The injection 
volume was 10.0 µL, flow rate was 0.8 mL/min and the column temperature 
was 30 oC. Total run time was 25 min. The following gradient elution program 
was used: 0-2 min 2% B, followed by an increase to 60% B within 15 min, 
followed by another increase to 80% B within 18 min before returning to 2% B 
within 25 min. 
 
High-resolution electrospray ionization-mass spectrometry (HR-ESI-MS) 
 
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap 
Discovery (Thermo Fisher Scientific, Bremen, Germany). Samples were 
dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) and infused 
at a rate of 5 µL/min. Full high mass accuracy scans (30,000) were performed 
in positive electrospray mode. Measured accurate masses were within ± 5 
ppm of the theoretical masses. The following conditions were used: drying 
gas (N2) 10 L/min, capillary temperature 310 oC, spray voltage 4 V, capillary 
voltage 22 V and tube lens 77 V. The mass calibration procedure was 
performed in both positive and negative mode using solutions of caffeine, L-
methionyl-arginyl-phenylalanyl-alanine acetate × H20 (MRFA), Ultramark 
1621®, sodium docecyl sulfate and sodium taurocholate. 
 
Nuclear magnetic resonance spectroscopy (NMR) 
 
All analytes were prepared in deuterated dimethyl sulfoxide (DMSO-d6) at a 
concentration of 20 mg/mL. 1H (600 MHz) and 13C (150 MHz) spectra were 
recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
1H NMR spectra were referenced to an external TMS reference at δ = 0 ppm 
 
X-ray crystallography 
 
Data for mexedrone were collected on a Bruker APEX DUO with Mo Kα 
radiation (λ = 0.71073 Å) using a MiTeGen micromount and at 100(2) K 
(Oxford Cobra Cryosystem). Bruker APEX2[34] software was used to collect 
and reduce data, determine the space group, solve and refine the structure. 
Absorption corrections were applied using SADABS.[35] All final refinements 
were performed with SHELXL.[36] All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were assigned to calculated positions using a 
riding model. CCDC 1452166 contains the supplementary crystallographic 
data for this paper. Crystal data and structure refinement parameters for 
mexedrone were as follows. C12H18ClNO2, M = 243.72, T = 100(2) K, 
Monoclinic, P21/n, a = 7.2107(2), 7.5947(2), c = 23.6179(7) Å, β = 
91.7912(11)°, V = 1292.76(6) Å3, Z = 4, µ (Mo Kα) = 0.282 mm−1, ρ = 1.252 
Mg/cm3, 25754 reflections collected, 3119 independent (Rint = 0.0290), aR1 = 
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0.0321, wR2 = 0.0800 (I > 2σ(I)), S = 1.075. CCDC 1452166.aR1 = Σ||Fo| − 
|Fc||/Σ|Fo|, wR2 = [Σw(Fo2 − Fc2)2/Σw(Fo2)2]1/2. 
 
 
Monoamine transporter assays 
 
Male Sprague-Dawley rats (250-300 g, Charles River Laboratories, 
Wilmington, MA, USA) were housed 2 per cage and maintained on a 12 h 
light-dark cycle. Food and water were provided ad libitum. Animal use 
procedures were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals, and the Animal Care and Use Committee of 
the Intramural Research Program of the National Institute on Drug Abuse 
(Baltimore, MD, USA). Rats were euthanized by CO2 narcosis and brains 
were processed to yield synaptosomes as previously described.[37,38] For 
uptake assays, synaptosomes were incubated with different concentrations of 
the test drugs in the presence of 5 nM [3H]dopamine, 10 nM 
[3H]norepinephrine, or 5 nM [3H]serotonin. The uptake assays were 
terminated by vacuum filtration and retained radioactivity was quantified by 
scintillation counting. For release assays, 9 nM [3H]-1-methyl-4-
phenylpyridinium ([3H]MPP+) was used as the radiolabelled substrate for 
dopamine transporters (DAT) and norepinephrine transporters (NET), while 5 
nM [3H]5-HT was used as the radiolabelled substrate for 5-HT transporters 
(SERT). All buffers used in the release assay methods contained 1 µM 
reserpine to block vesicular uptake of substrates. The selectivity of release 
assays was optimized for a single transporter by including unlabeled blockers 
to prevent the uptake of [3H]MPP+ or [3H]5-HT by competing transporters. 
Synaptosomes were preloaded with radiolabelled substrate in Krebs-
phosphate buffer for 1 h (steady state). Release assays were initiated by 
adding 850 µL of preloaded synaptosomes to 150 µL of test drug. The release 
assays were terminated by vacuum filtration and retained radioactivity was 
quantified by scintillation counting. 
  
Results and discussion 
 
Both the analytical and pharmacological characterization of mephedrone has 
been well documented in the scientific literature[8-26] and studies focusing 
specifically on synthesis related by-products have also been conducted.[39] 
The cathinone molecular scaffold gives rise to a large range of biologically 
active compounds. Synthetic cathinones remain a popular choice amongst 
drug users and are the second largest family of compounds monitored by the 
EMCDDA Early Warning Network.[8,11] The structural diversity of the cathinone 
analogs present analytical challenges for forensic scientists who are trying to 
identify new analogs in drug seizures and/or toxicological samples. 
Mephedrone was subjected to European-wide control measures in 2010 and 
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since then NPS suppliers and recreational drug users anticipated the 
provision of a non-controlled replacement. Almost five years later, in August 
2015, the novel synthetic cathinone mexedrone, 3-methoxy-2-(methylamino)-
1-(4-methylphenyl)propan-1-one, reached the NPS market. The only 
structural difference between mexedrone and mephedrone is the addition of a 
methoxy group to position 3 in the propan-1-one sequence, which meant that 
it fell outside of the generic definitions of controlled cathinones that are 
operating in the UK and Ireland.[40-42] 
 
The synthesis procedure for N-methoxymephedrone involved reacting alpha-
bromo-4-methylpropiophenone (a) with N,O-dimethylhydroxylamine 
hydrochloride and N,N-diisopropylethylamine, which yielded the product (b) 
as a yellow oil (Figure 1B). Formation of the hydrochloride salt was conducted 
using a solution (2 M) of hydrogen chloride in diethyl ether, followed by 
trituration with tert.-butyl methyl ether, which afforded the N-methoxy analog 
as a colorless solid. The synthesis procedure employed for the preparation of 
mexedrone involved reacting 3-chloro-1-(4-methylphenyl)propan-1-one (c) 
with sodium iodide and sodium methoxide yielding 3-methoxy-1-(4-
methylphenyl)propan-1-one (d). This was then reacted with bromine yielding 
2-bromo-3-methoxy-1-(4-methylphenyl)propan-1-one (e). This intermediate 
was dissolved in acetonitrile and methanolic methylamine was added, yielding 
the desired product 3-methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-
one (f) as a brown oil (Figure 1C). This was then treated with hydrogen 
chloride in diethyl ether and washed with acetone for the formation of the 
hydrochloride salt, followed by recrystallization from ethanol to afford 
mexedrone HCl as colorless crystals. During the synthesis of mexedrone, a 
route specific chlorinated by-product was observed (Supporting Information). 
The structure of this by-product was elucidated as 3-chloro-2-(methylamino)-
1-(4-methylphenyl)propan-1-one (α-chloromethylmephedrone). It is suggested 
that 3-chloro-1-(4-methylphenyl)propan-1-one failed to undergo complete 
conversion to 3-methoxy-1-(4-methylphenyl)propan-1-one. The unreacted 3-
chloro-1-(4-methylphenyl)propan-1-one (g) would have then reacted with the 
bromine yielding 2-bromo-3-chloro-1-(4-methylphenyl)propan-1-one (h). This 
brominated species would then have continued through the synthesis stages, 
reacting with methanolic methylamine to yield 3-chloro-2-(methylamino)-1-(4-
methylphenyl)propan-1-one (i), which was subsequently converted to its HCl 
salt form. The identification was confirmed through targeted organic synthesis 
of the chlorinated by-product (Figure 1D). 
 
This present investigation reports on the synthesis and characterization of 
mexedrone and its N-methoxy positional isomer, N-methoxymephedrone. The 
analysis of the vendor sample revealed that it was consistent with mexedrone. 
The analysis also revealed high purity as judged by chromatographic 
characterizations and nuclear magnetic resonance (NMR) spectroscopy. 
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However, traces of isopropyl alcohol were observed in the NMR proton 
spectrum of the vendor sample, and it is surmised that this isopropyl alcohol 
contamination arose from the recrystallization process (Supporting 
Information). 
 
In Ireland, one of the main pieces of legislation governing drugs and drug use 
is the Misuse of Drugs Act 1977, which was recently amended by the Misuse 
of Drugs (Amendment) Act 2015. In the UK, the Misuse of Drugs Act 1971 
(updated by Amendment Orders) is operating. In both cases, synthetic 
cathinones are controlled substances by way of generic definitions 
(exceptions apply) based on modifications of the 2-amino-1-phenyl-1-
propanone or 2-aminopropan-1-one template.[40-42] Interestingly, it was 
observed that these generic controls cannot be applied to mexedrone, N-
methoxymephedrone, or indeed the chlorinated by-product identified, as the 
legislation does not include the addition of a methoxy moiety or halogen atom 
at position 2- and 3- of the propanone side chain or at the nitrogen based 
terminus. This fact highlights a possible flaw in generic control legislation, 
which can be ambiguous and NPS manufacturers will always seek ways and 
means to circumvent it. However, whether these modifications lead to 
substances with desired psychoactive properties is another question. 
 
 
Analytical features 
 
Gas chromatography-mass spectrometry (GC-MS) 
 
Separation of both isomers was successfully achieved using gas 
chromatography (GC). The retention times for mexedrone and its N-methoxy 
positional isomer were 6.57 and 6.18 min, respectively (Figure 2A and B), and 
a comparison with the vendor sample was in agreement with the identity of 
the former (Supporting Information). A comparison of both electron ionization 
mass spectra (EI-MS) demonstrated that both isomers shared common 
fragmentation patterns apart from two fragments that provided important 
distinguishing features (Figure 2A and B). In the EI-MS of mexedrone, a 
fragment at m/z 162 was observed and may be interpreted as the loss of 
methoxyethane from the parent compound, resulting in the formation of a 
methanaminium ion (C10H12NO+). This peak at m/z 162 was not observed in 
the EI-MS of N-methoxymephedrone and instead a fragment at m/z 192 was 
observed. This fragment could represent the formation of a 
hydroxylammonium ion (C11H14NO2+) formed by the loss of a methyl group 
from the parent structure. The base peak was observed at m/z 88 in both EI 
mass spectra. In the case of mexedrone, the m/z 88 was interpreted as the 
formation of another methanaminium ion (C4H10NO+) following the loss of the 
(4-methylbenzylidyne)oxonium ion from the parent structure. A loss of the 
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same species from N-methoxymephedrone might have given rise to the 
formation of a hydroxylammonium ion (C4H10NO+) at m/z 88. Several common 
fragments were observed in the mass spectra of both isomers, including 
fragments at m/z 119, m/z 56 and m/z 42. The fragment at m/z 119 appeared 
to represent the formation of the benzoyl ion (C8H7O+). The fragment at m/z 
56 could be a N-ethylidynemethanaminium species and loss of a methylene 
group from this entity would lead to the fragment observed at m/z 42, which 
was thought to be an ethylidyneammonium ion. The molecular ion was 
detected at m/z 207 but the relative abundance was negligible. The vendor 
sample shared the same mass spectral characteristics compared to the 
synthesized mexedrone reference standard. The proposed electron ionization 
fragmentation patterns for both mexedrone and N-methoxymephedrone are 
outlined in Figure 2C. 
 
Liquid chromatography-mass spectrometry (LC-MS) 
 
Separation of mexedrone from the N-methoxymephedrone isomer was 
successfully achieved using liquid chromatography (LC). The retention times 
obtained for mexedrone and N-methoxymephedrone were 8.01 and 10.63 
min, respectively, and a comparison with the vendor sample was in 
agreement with the identity of the former (Supporting Information). The 
electrospray ionization (ESI) single quadrupole mass spectra obtained from 
in-source collision-induced dissociation (CID) of the synthesized isomers (110 
V fragmentor voltage) shared similar fragmentation patterns but key features 
that allowed differentiation between the two substances were also present 
(Figure 3A and B). The suggested dissociation pathways are shown in Figure 
4A and B. For example, the in-source CID spectrum of mexedrone displayed 
a sodiated adduct [M + Na]+ at m/z 230, which was not present in the in-
source CID spectrum of N-methoxymephedrone. Th  protonated molecule [M 
+ H]+ was present in both mass spectra at m/z 208 with a relative abundance 
of approximately 40% and 15% for mexedrone and N-methoxymephedrone, 
respectively. In the mass spectrum of mexedrone, a fragment at m/z 190 was 
observed and may be interpreted as the loss of water from the protonated 
molecule. This fragment was not present in the in-source CID spectrum of N-
methoxymephedrone. The fragment observed at m/z 176 was interpreted as 
the formation of an aminium ion (C11H14NO+) following the loss of methanol 
from protonated mexedrone (Figure 4A). A m/z 176 species was also 
observed in the mass spectrum of N-methoxymephedrone but was 
considered representative of the formation of an iminium ion species 
(C11H14NO+), again following the loss of methanol from the protonated parent 
structure (Figure 4B). The relative abundance of this fragment varied between 
isomers and was much higher in the mass spectrum of mexedrone (70%) 
compared to N-methoxymephedrone (10%). In the mass spectrum of 
mexedrone, the base peak was observed at m/z 158 and thought to have 
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arisen from the loss of methanol from the ion at m/z 190 to result in the 
formation of a methylium species (C11H12N+). In the mass spectrum of N-
methoxymephedrone, the base peak was observed at m/z 119 and 
represented by the formation of the benzoyl species (C8H7O+). This particular 
ion was also detected in the mass spectrum of mexedrone but at a lower 
abundance (60%). Further cleavage of CO from this oxonium ion resulted in 
the formation the tropylium ion at m/z 91 and it was detected in the mass 
spectra of both isomers, although at a higher relative abundance in the mass 
spectrum of N-methoxymephedrone (40%). The mass spectrum of the vendor 
sample was consistent with that of the synthesized mexedrone reference 
standard (Supporting Information). Implementation of high resolution mass 
spectrometry provided elemental compositions with acceptable mass 
accuracies consistent with the proposed structures of the product ions (Figure 
4A and B). 
 
 
X-ray Crystallography 
 
The solid-state structure of mexedrone was examined using single crystal X-
ray diffraction from crystals grown from a methanol solution as the HCl salt. 
The structure of mexedrone is shown in Figure 5. The ion pair crystallized in 
the monoclinic centrosymmetric space group P21/n as a racemic mixture. The 
cathinone skeleton in mexedrone and related congeners in the literature were 
similar and an overlay of the skeleton (matching enantiomer, fitting C2-C8, 
O9) showed a RMS deviation from fit of 0.015-0.072 Å for seven examples.[43-
46]
 The ions in mexedrone HCl were linked by N-H…Cl and CH…Cl hydrogen 
bonds (N11…Cl1, 3.084(1)Å; C10…Cl1#, 3.458(1)Å; symmetry transformation 
# = -x+3/2,y-1/2,-z+1/2). Strong hydrogen bonding between salts formed an 
extended dimeric chain that propagated parallel to the crystallographic b-axis. 
Weak C-H…O interactions (C7…O9*, 3.359(2)Å; * = 2+x, y, z) also assisted in 
the structural arrangement. Information on the cell packing is provided as 
Supporting Information. Aromatic π- π stacking was not seen in this structure, 
which differed from what was observed in the structure of pentedrone HCl.[45] 
 
 
Nuclear magnetic resonance spectroscopy (NMR) 
 
The NMR spectra associated with mexedrone and N-methoxymephedrone 
shared some key characteristics, such as the proton and carbon signals 
associated with aromatic ring, carbonyl moiety (β-carbon) and N-methyl 
group. However, several structural features also facilitated differentiation 
between the two isomers. The significant differences occurred at the chemical 
environments around both the nitrogen and α-carbon atom. For example, the 
proton signals associated with the nitrogen terminus were observed at 9.65 
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and 9.21 ppm in the 1H NMR spectrum of mexedrone. These signals were not 
detected in the 1H NMR spectrum of N-methoxymephedrone as the nitrogen 
atom, in this case, is connected to methyl and methoxy moieties, which were 
observed at 2.60 and 3.18 ppm, respectively. Further distinguishing features 
included the proton signals associated with the methylene group on the α-
carbon atom at 4.00 and 3.82 ppm in the 1H NMR of mexedrone. These 
signals were not detected in the 1H NMR spectrum of N-methoxymephedrone. 
Instead, a proton signal affiliated with the methyl group (1.20 ppm) attached to 
the α-carbon atom was observed. In the 13C NMR spectrum of mexedrone, a 
carbon signal was observed at 63.57 ppm and is associated with methylene 
group attached to the α-carbon atom. This carbon signal was absent in the 
13C NMR spectrum of N-methoxymephedrone and a carbon signal was 
observed at 12.63 ppm instead. This signal was associated with the carbon of 
the methyl group attached to the α-carbon atom. The 1H and 13C NMR 
spectral data of the vendor product were in agreement with GC and LC data 
confirming the presence of mexedrone. Furthermore, the NMR spectra 
associated with mexedrone and the α-chloromethylmephedrone also shared 
mainly similar characteristics. The major distinguishing features between 
these two isomers were the presence of carbon and proton signals 
representing the methyl group of the methoxy moiety present in the 
mexedrone chemical structure. As expected, these signals were not detected 
in the NMR spectral data for α-chloromethylmephedrone. 
 
During the characterization of N-methoxymephedrone, it was noticed that the 
compound had hygroscopic properties and that it was unstable in its 
crystalline form, and over time, would convert from a colorless solid to a 
brown solid. An additional chromatographic peak was noticed during LC-MS 
analysis of a second synthesized batch of N-methoxymephedrone 
(Supporting Information). Examination of the analytical data revealed this 
impurity as mephedrone. Integration using NMR proton signals confirmed that 
N-methoxymephedrone reference standard contained approximately 6% 
mephedrone (Supporting Information). A LC-MS time study was set up to 
examine whether the presence of mephedrone was due to a synthesis related 
by-product or degradation of the N-methoxymephedrone to mephedrone over 
time. It was considered possible that the presence of mephedrone may have 
been due to hydrolysis of the N-methoxy isomer to mephedrone. However, it 
was equally possible that the mephedrone was a synthesis by-product. After 
LC-MS analysis, the presence of mephedrone was considered unlikely to 
result from degradation as the concentration of mephedrone in the N-
methoxymephedrone reference standard remained constant over 24 hours 
under conditions of the LC mobile phase and aqueous release assay buffer 
conditions. Therefore, it was concluded the mephedrone was present as a 
synthesis by-product. 
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Monoamine transporter activity 
 
Figure 6A-C shows the effects of mexedrone, N-methoxymephedrone, and α-
chloromethylmephedrone on the uptake of [3H]dopamine, [3H]norepinephrine, 
and [3H]serotonin by their respective transporters DAT, NET, and SERT. The 
corresponding IC50 values for inhibition of uptake are provided in Table 1 and 
mephedrone was included for comparison. As revealed from the dose-
response curves, the α-chloromethylmephedrone impurity did not display any 
ability to inhibit transporter uptake, whereas the remaining substances were 
fully efficacious uptake blockers with potency in the low micromolar range 
(Table 1). Mexedrone and its isomer N-methoxymephedrone showed 
comparable potency at DAT (IC50 = 6.84 and. 6.09 µM), but the latter 
compound was 2.6- and 1.6-fold more potent at NET and SERT, respectively. 
Importantly, mephedrone was more potent than all three test drugs at DAT, 
NET and SERT. The IC50 values for mephedrone reported here agreed with 
those published previously under similar experimental conditions.[47]  
 
Given that mephedrone has been established as a substrate-type releasing 
agent both in vitro and in vivo (e.g.[38,47-51]), further investigations were carried 
out to assess whether mexedrone, N-methoxymephedrone and α-
chloromethylmephedrone would display releasing properties. The results, also 
derived from rat brain synaptosomes, are displayed in Figure 6D-F. The data 
demonstrate that only mephedrone and N-methoxymephedrone exhibited the 
expected S-shaped dose-response curve for a fully-efficacious releaser 
across all three transporters. The potency values are shown in Table 2, which 
illustrates that mephedrone, consistent with data reported before,[38,47-48] was 
a potent substrate for all three transporters with slightly higher selectivity for 
catecholamine transporters. Although less potent than mephedrone (Table 2), 
N-methoxymephedrone was found to be a fully fficacious substrate-type 
releasing agent for all three transporters with EC50 values in the low 
micromolar range. α-Chloromethylmephedrone was inactive in all assays. 
Mexedrone displayed interesting pharmacological properties in the release 
assays. Specifically, the drug was inactive as a releaser at DAT and NET, but 
displayed weak releasing activity at SERT (Table 2, Figure 6D-F). Taken 
together with the uptake data, it is apparent that mexedrone displays “hybrid” 
activity at monoamine transporters wherein the drug acts as an uptake 
blocker at DAT and NET but a substrate at SERT. The present and other 
authors have previously reported this type of activity for cathinone-related 
compounds such as 4-methyl-N-ethylcathinone.[52-53]  
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Conclusion 
 
This report provides comprehensive analytical and pharmacological data on 
the NPS mexedrone, as well as data on its N-methoxy positional isomer, N-
methoxymephedrone. The ability of N-methoxymephedrone to act as a fully 
efficacious reuptake inhibitor and substrate-type releaser could provide a 
stimulus for further drug developments. On the other hand, the observation 
that synthesis of N-methoxymephedrone could be prone to contain 
mephedrone as an impurity might preclude this substance from being 
developed as a commercially viable NPS on a larger scale. From this 
perspective, it is tempting to speculate that mexedrone was developed as an 
alternative to N-methoxymephedrone as it seems conceivable that 
mephedrone impurities in the latter compound would have been observed by 
manufacturers during the development stage. The pharmacological data 
suggest that N-methoxymephedrone showed a transporter-meditated 
releasing profile comparable to mephedrone although much lower in potency. 
By contrast, mexedrone was found to be a weak monoamine transporter 
uptake blocker and weak serotonin releasing agent, which might explain why 
this substance received poor reviews on user forums.  
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1. Figure captions 
 
Figure 1. A: Chemical structures of mephedrone, mexedrone and isomeric N-
methoxymephedrone. B-C: Synthesis pathways employed for mexedrone and N-
methoxymephedrone. D: Synthesis pathway employed for the route specific 
chlorinated by-product. 
 
Figure 2. Gas chromatography mass spectrometry data. A and B: Electron ionization 
mass spectra for mexedrone and N-methoxymephedrone. C:  Proposed 
fragmentation pattern for both isomers. 
 
Figure 3. A and B: Product ion spectra of synthesized mexedrone and N-
methoxymephedrone obtained from in-source collision induced dissociation (CID) at 
increased fragmentor voltage (110 V). Insert: Partial HPLC ESI single quadrupole 
MS trace to illustrate the separation of both isomers.  
 
Figure 4. The suggested dissociation pathways for mexedrone (A) and N-
methoxymephedrone (B) with HR-MS providing elemental compositions with 
acceptable mass accuracies consistent with the proposed structures. 
 
Figure 5. Molecular structure recorded for the mexedrone vendor sample using x-ray 
crystal structure analysis. 
 
Figure 6. Effects of mexedrone, N-methoxymephedrone, α-chloromethylmephedrone 
and comparison test drug mephedrone on inhibition of uptake and stimulation of 
release at DAT, NET, and SERT in rat brain synaptosomes. For uptake assays (A, B, 
and C), synaptosomes were incubated with different concentrations of the test drugs 
in the presence of 5 nM [3H]dopamine (A, for DAT), 10 nM [3H]norepinephrine (B, for 
NET), or 5 nM [3H]serotonin (C, for SERT). Data are expressed as percentage of 
[3H]transmitter uptake (mean ± SD) for n = 3 experiments. For release assays (D, E, 
and F), synaptosomes were preloaded with 9 nM [3H]MPP+ for DAT (D) and NET (E), 
or 5 nM [3H]serotonin for SERT (F), then incubated with different concentrations of 
test drugs to evoke release via reverse transport. Data are expressed as percentage 
of [3H]substrate release (mean ± SD) for n = 3 experiments. 
 
Table 1. Effects of test drugs on transporter uptake inhibition from rat brain 
synaptosomes. 
 
Table 2. Effects of test drugs on transporter-mediated release from rat brain 
synaptosomes. 
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Figure 1. A: Chemical structures of mephedrone, mexedrone and isomeric N-methoxymephedrone. B-C: 
Synthesis pathways employed for mexedrone and N-methoxymephedrone. D: Synthesis pathway employed 
for the route specific chlorinated by-product.  
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Figure 2. Gas chromatography mass spectrometry data. A and B: Electron ionization mass spectra for 
mexedrone and N-methoxymephedrone. C:  Proposed fragmentation pattern for both isomers.  
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Figure 3. A and B: Product ion spectra of synthesized mexedrone and N-methoxymephedrone obtained from 
in-source collision induced dissociation (CID) at increased fragmentor voltage (110 V). Insert: Partial HPLC 
ESI single quadrupole MS trace to illustrate the separation of both isomers.  
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Figure 4. The suggested dissociation pathways for mexedrone (A) and N-methoxymephedrone (B) with HR-
MS providing elemental compositions with acceptable mass accuracies consistent with the proposed 
structures.  
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Figure 5. Molecular structure recorded for the mexedrone vendor sample using x-ray crystal structure 
analysis.  
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Figure 6. Effects of mexedrone, N-methoxymephedrone, α-chloromethylmephedrone and comparison test 
drug mephedrone on inhibition of uptake and stimulation of release at DAT, NET, and SERT in rat brain 
synaptosomes. For uptake assays (A, B, and C), synaptosomes were incubated with different concentrations 
of the test drugs in the presence of 5 nM [3H]dopamine (A, for DAT), 10 nM [3H]norepinephrine (B, for NET), 
or 5 nM [3H]serotonin (C, for SERT). Data are expressed as percentage of [3H]transmitter uptake (mean ± 
SD) for n = 3 experiments. For release assays (D, E, and F), synaptosomes were preloaded with 9 nM 
[3H]MPP+ for DAT (D) and NET (E), or 5 nM [3H]serotonin for SERT (F), then incubated with different 
concentrations of test drugs to evoke release via reverse transport. Data are expressed as percentage of 
[3H]substrate release (mean ± SD) for n = 3 experiments.  
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Table 1. Effects of test drugs on transporter uptake inhibition from rat brain 
synaptosomes 
 
Test drug [3H]DA 
uptake via  
DAT IC50  
(nM) 
[3H]NE 
uptake via 
NET IC50 
(nM) 
[3H]5-HT 
uptake via 
SERT IC50 
(nM) 
Mephedrone 1056 ± 85 494  ± 93 470 ± 7.6 
Mexedrone 6844 ± 1522 8869 ± 3103 5289 ± 1624 
N-Methoxymephedrone 6091 ± 1615 3457 ± 728 3334 ± 1129 
α-Chloromethylmephedrone inactive inactive inactive 
 
Data are expressed as nM concentrations (mean ± SD) for n = 3 separate 
experiments performed in triplicate. Inactive refers to no inhibition at 10,000 nM. 
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Table 2. Effects of test drugs on transporter-mediated release from rat brain 
synaptosomes 
 
Test drug [3H]MPP+ 
release via 
DAT EC50 
(nM) 
[3H]MPP+ 
release via 
NET EC50 
(nM) 
[3H]5-HT 
release via 
SERT EC50 
(nM) 
Mephedrone 45 ± 6 58  ± 7 163 ± 30 
Mexedrone inactive inactive 2525 ± 560 
N-Methoxymephedrone 666 ± 132 313 ± 51 1043 ± 271 
α-Chloromethylmephedrone inactive inactive inactive 
 
Data are expressed as nM concentrations (mean ± SD) for n = 3 separate 
experiments performed in triplicate. Inactive refers to efficacy less than 33% of 
maximal release. 
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